
Jonathan Peled, MD, PhD
Bone Marrow Transplant Specialist & Cellular Therapist
Titles
Assistant Attending Physician
Clinical Expertise
Hematopoietic Cell Transplantation (Bone Marrow Transplantation); Cellular Therapy
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Contact and Location
- 646-888-2105 Office Phone
- Speaks English

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, PhD, Albert Einstein College of Medicine
Residencies
Internal Medicine, Massachusetts General Hospital
Fellowships
Medical Oncology and Hematology, Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine; Medical Oncology
Please note that Dr. Peled’s clinical practice is dedicated to the care of hospitalized patients. He does not accept appointments.
I am a medical oncologist who specializes in bone marrow transplantation and cellular therapies for blood cancers, including leukemias, multiple myeloma, myelodysplastic syndrome, and lymphoma.
I have always been interested in biology, cancer, and the immune system. I chose a career in oncology because of the exciting developments ongoing in the field and the opportunity to form deep relationships with patients and their families. When caring for patients, I try to consider the patient’s and family’s needs holistically. I strive to pay attention to all the technical details without losing sight of the bigger picture — the patient’s goals, values, and quality of life.
Read more
Bone marrow transplantation in particular is a powerful way to potentially cure cancers of the blood, and I am interested in how the transplanted immune system from the donor accomplishes this. One of the major problems in bone marrow transplantation is graft-versus-host disease (GVHD), a complication that can occur after a stem cell or bone marrow transplant. GVHD can happen when donor’s immune system attacks the patient’s organs. If we can find a way to reduce or eliminate this problem, many more patients could benefit from the cures that transplantation can offer. This is the motivation that drives the research I do alongside providing patient care.
I also run a laboratory that studies how the bacteria that live within our intestines — the microbiome —affect our immune system and the success of cancer immunotherapy.
I live in Westchester County with my wife and three sons and enjoy theater and tennis.
Awards and Honors
- Best Abstract Award, American Society of Bone Marrow Transplantation (2016, 2018, and 2019)
- Community Service Award, Medical Society of the State of New York (2010)
- Alpha Omega Alpha (2009)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, Burgos da Silva M, Khan N, Gessner A, Messina JA, Romero K, Lew MV, Bush A, Bohannon L, Brereton DG, Fontana E, Amoretti LA, Wright RJ, Armijo GK, Shono Y, Sanchez-Escamilla M, Castillo Flores N, Alarcon Tomas A, Lin RJ, Yáñez San Segundo L, Shah GL, Cho C, Scordo M, Politikos I, Hayasaka K, Hasegawa Y, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Jenq RR, Teshima T, Chao NJ, Holler E, Xavier JB, Pamer EG, van den Brink MRM. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020 Feb 27;382(9):822-834. doi: 10.1056/NEJMoa1900623. PMID: 32101664; PMCID: PMC7534690.
Schluter J, Peled JU, Taylor BP, Markey KA, Smith M, Taur Y, Niehus R, Staffas A, Dai A, Fontana E, Amoretti LA, Wright RJ, Morjaria S, Fenelus M, Pessin MS, Chao NJ, Lew M, Bohannon L, Bush A, Sung AD, Hohl TM, Perales MA, van den Brink MRM, Xavier JB. The gut microbiota is associated with immune cell dynamics in humans. Nature. 2020 Dec;588(7837):303-307. doi: 10.1038/s41586-020-2971-8. Epub 2020 Nov 25. PMID: 33239790; PMCID: PMC7725892.
Khan N, Lindner S, Gomes ALC, Devlin SM, Shah GL, Sung AD, Sauter CS, Landau HJ, Dahi PB, Perales MA, Chung DJ, Lesokhin AM, Dai A, Clurman A, Slingerland JB, Slingerland AE, Brereton DG, Giardina PA, Maloy M, Armijo GK, Rondon-Clavo C, Fontana E, Bohannon L, Ramalingam S, Bush AT, Lew MV, Messina JA, Littmann E, Taur Y, Jenq RR, Chao NJ, Giralt S, Markey KA, Pamer EG, van den Brink MRM, Peled JU. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood. 2021 Mar 18;137(11):1527-1537. doi: 10.1182/blood.2020006923. PMID: 33512409; PMCID: PMC7976512.
Read more
Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science. 2019 Nov 29;366(6469):1143-1149. doi: 10.1126/science.aax3760. PMID: 31780560; PMCID: PMC7003985.
Visit PubMed for a full listing of Dr. Peled’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jonathan Peled discloses the following relationships and financial interests:
-
Arjun Pai
Provision of Services -
CSL Behring
Provision of Services -
Japanese Society of Hematology
Provision of Services (uncompensated) -
Keio University
Provision of Services
-
MaaT Pharma
Provision of Services -
Postbiotics Plus Research, LLC
Ownership / Equity Interests; Provision of Services (uncompensated) -
Seres Therapeutics
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].